Canagliflozin API
CAS.NO:842133-18-0
structural formula:C24H25FO5S
EINECS.no:695-192-1
Other names:TA 7284;Cagliflozin;CS-183;Invokana;Canagliflozin(TA-7284)；Canaglifozion；Canagliflozin
Test Method:HPLC/UV/GC-MS
MOQ & Package: 10g,100g,1kg,5kg,10kg,25kg etc
Customer's rights and interests:Over 10kg, you can enjoy the service of giving away free samples.
Certificate：FDA,ISO,COA, HPLC, MSDS,TDS etc
Lead Time: 1-3 days
Shipping: DHL,Germany DHL,Germany DPD,UPS,USPS,FedEx,EMS,By Air,By Sea,multimodal transport etc
Store & Shelf life; Cool & dry place; 36 months
Company advantages: there are self-built overseas warehouses and third-party overseas warehouses on all continents.
- Product Description
Xi'an Faithful BioTech Co., Ltd: Your Trusted Canagliflozin API Manufacturer & Supplier
Canagliflozin API is an SGLT2 inhibitor, which can reduce blood sugar by decomposing glucose and excreting it from the body through the kidney. Besides good blood sugar control, the most striking advantage of Canagliflozin powder we provide is its weight-reducing effect and few hypoglycemia events. At present, weight loss is on the market, and it is one of the most promising candidate materials for weight loss in Xi'an Faithful BioTech Co., Ltd Company.
Canagliflozin API Introduction
Canagliflozin Powder is an efficient and selective inhibitor of sodium glucose cotransporter 2 (SGLT2), which acts on hSGLT2 with an IC50 of 2.2 nM in cell-free assays, showing 413 times higher selectivity than hSGLT1. In clinical trials, TA 7284 powder mainly lowers the body's blood glucose levels by blocking the reabsorption of blood glucose by the kidneys and increasing the excretion of blood glucose in urine. According to current medical knowledge, compared with people without diabetes, the kidneys of patients with type 2 diabetes can reabsorb a large amount of glucose into the blood, which may push up the blood sugar level. So, compared to the single action of pancreatic islets in other hypoglycemic drugs, the target and mechanism of SGLT-2 are different, creatively opening up a new path for hypoglycemic treatment. Clinical trials have found that the mechanism of action of JNJ 28431754 does not depend on pancreatic beta cells, so its activity is not affected by the function of pancreatic beta cells. Therefore, Canagliflozin API can be used at any stage of coping with type 2 diabetes patients.
Specifications
Item | Specifications | Results | |
Appearance | White or light yellow powder | Complies |
|
Purity | ≥ 98.00% | Complies |
|
Identification | Positive | Complies |
|
PH | 5.0~7.5 | 6.50 | |
Color of solution | Colorless | Complies |
|
Clarity of solution | Clear | Complies |
|
| Conclusion | Conform with enterprise specification （USP 41）. |
Why Choose Us?
Our Canagliflozin API Powder not only maintains purity ≥ 99.0%, but also strictly controls impurity content within 1.0%, with single impurities less than 0.5%, peptide content ≥ 80.0%, endotoxin ≤ 50EU/mg, and all quality indicators comply with international pharmacopoeia standards such as CP, USP, BP, and EP. Moreover, we actively upgrade our equipment and adopt the most advanced multi-step continuous flow synthesis process, which significantly improves production efficiency compared to traditional batch reactor processes and can meet your different procurement needs.
Our CS-183 powder have passed international authoritative certifications such as FDA and EDQM, and comply with regulatory requirements in major global markets. Each batch of products comes with a complete Certificate of Analysis (COA) to ensure that every step from raw material procurement to finished product delivery complies with Good Manufacturing Practice (GMP) requirements. To sum up, our API Canagliflozin(TA-7284) are more competitive in price and cost-effective, which is an ideal choice for the development of diabetes Pharmaceutical raw materials.
Our email address is:sales8@faithfulbio.com, Welcome your letter.
Application prospect:
The current hypoglycemic raw materials are insulin, DPP-IV inhibitor, GLP-1 receptor agonist and SGLT-2 inhibitor in order of global market share. According to the analysis of market share of various hypoglycemic drugs in 2024 by a large enterprise, insulin will still have the largest market share among all diabetes drugs in 2024. GLP-1 receptor agonist expands rapidly, and its share is second only to insulin. SGLT-2 inhibitor will crowd out DPP-4 inhibitor and become the king in the future. Canaglifozion API, as the first SGLT2 inhibitor approved by FDA, targets type 2 sodium glucose cotransporter (SGLT2). The effectiveness and safety of the drug have been confirmed by existing clinical trials. When used alone or in combination with metformin and sulfonylureas, it can significantly reduce HbA1c and fasting blood glucose in patients with type 2 diabetes, with extremely low incidence of adverse reactions and low risk of hypoglycemia, and can significantly reduce body weight.
Quality Control:
R&D Results:
Packaging and Transportation:
After-Sales Service:
Qualification Certification:
Transaction Feedback:
Exhibition:
FAQ
Q1: What are its advantages compared to other SGLT2 inhibitors?
It is the first SGLT2 inhibitor to receive FDA approval, supported by abundant clinical research data. Compared with Glimepiride powder, it is superior in reducing HbA1c and has a lower incidence of serious adverse events (5% vs 8%). In addition, Canagliflozin API also has cardiovascular and renal protective effects.
Q2: How is its production process?
It adopts continuous flow technology for multi-step synthesis. Compared with the traditional batch reactor process (42% yield), multi-step continuous flow synthesis can achieve a yield of 76% and a product purity of 99.97%. The lowest reaction temperature only needs to be controlled at -18 ℃, and the total reaction time of 4 steps is only 44 seconds.
Q3: What are the storage conditions for Anagliflozin API?
Canagliflozin API powder should be stored in a dry, ventilated, and dark environment, avoiding contact with oxidants, reducing agents, and other substances. Suggested storage temperature is -20 ℃, and the storage period is generally two years.
Contact us
A number of studies have shown that Cagliflozin powder can effectively improve blood sugar control, reduce body weight, blood pressure, blood lipid and uric acid, and can protect the heart and kidney of patients, reduce complications and improve the prognosis of patients. If you have this topic, please leave me a message:sales8@faithfulbio.com .I will provide you with a satisfactory solution in combination with the company policy.
